157 Spam-Free Article(s) Found
Symbol Name Last Close Mkt Cap DailyStocks'
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Tuesday’s Close
NVO Novo Nordisk A/S $47.64 $114.84B Downtrend
Article Searches
4 Buy-Ranked Large Cap Pharma Stocks to Boost Your Portfolio http://www.zacks.com/stock/news/294071/4-buy-ranked-large-cap-pharma-stocks-to-boost-your-portfolio?cid=CS-ZC-FT-294071 Feb 28, 2018 - Though the large-cap pharma sector struggled a little after a strong start in 2018, it is largely expected to rebound as the year progresses.
M&A, Innovation & New Drugs to Drive Pharma Stocks http://www.zacks.com/commentary/152408/ma-innovation-new-drugs-to-drive-pharma-stocks?cid=CS-ZC--152408 Mar 08, 2018 - M&A, Innovation & New Drugs to Drive Pharma Stocks
Diabetes Devices Market on a Tear: 3 Stocks for Solid Returns http://www.zacks.com/stock/news/295726/diabetes-devices-market-on-a-tear-3-stocks-for-solid-returns?cid=CS-ZC-FT-295726 Mar 15, 2018 - Consider these three stocks in the rapidly-growing diabetes devices market for grand returns.
Novo Nordisk Obtains Licence for Sickle Cell Disease Program http://www.zacks.com/stock/news/298364/novo-nordisk-obtains-licence-for-sickle-cell-disease-program?cid=CS-ZC-FT-298364 Apr 06, 2018 - Novo Nordisk (NVO) secures a global licence for United States' biotech company EpiDestiny's sickle cell disease program EPI01.
Novo Nordisk (NVO) Beats Q1 Earnings Estimates, Sales Miss http://www.zacks.com/stock/news/301962/novo-nordisk-nvo-beats-q1-earnings-estimates-sales-miss?cid=CS-ZC-FT-301962 May 02, 2018 - Novo Nordisk's (NVO) first-quarter 2018 results beat earnings, but missed on revenue estimates.
Novo Nordisk to Restructure R&D Unit & Lay Off 400 Staff http://www.zacks.com/stock/news/323818/novo-nordisk-to-restructure-rd-unit-lay-off-400-staff?cid=CS-ZC-FT-323818 Sep 19, 2018 - Novo Nordisk (NVO) plans to restructure and reallocate resources in its Research and Development organization and lay off 400 employees from the unit.
PFE or NVO: Which Is the Better Value Stock Right Now? http://www.zacks.com/stock/news/327938/pfe-or-nvo-which-is-the-better-value-stock-right-now?cid=CS-ZC--327938 Oct 15, 2018 - PFE vs. NVO: Which Stock Is the Better Value Option?
Novo Nordisk (NVO) Q4 Earnings Miss Estimates, Revenues Beat http://www.zacks.com/stock/news/351653/novo-nordisk-nvo-q4-earnings-miss-estimates-revenues-beat?cid=CS-ZC-FT-351653 Feb 01, 2019 - Novo Nordisk (NVO) fourth-quarter 2018 results mainly benefit from strong performance by Ozempic.
Merck's Keytruda Clinches CHMP Nod for Difficult Lung Cancer http://www.zacks.com/stock/news/352085/mercks-keytruda-clinches-chmp-nod-for-difficult-lung-cancer?cid=CS-ZC-FT-352085 Feb 05, 2019 - Merck (MRK) secures a positive verdict from the Committee for Medicinal Products for Human Use to approve Keytruda's combo therapy for first-line treatment of a difficult lung cancer population.
Sanofi (SNY) Q4 Earnings Top, Genzyme Unit Drives Sales Growth http://www.zacks.com/stock/news/352788/sanofi-sny-q4-earnings-top-genzyme-unit-drives-sales-growth?cid=CS-ZC-FT-352788 Feb 07, 2019 - Sanofi (SNY) beat estimates for earnings and missed the same for sales in the fourth quarter. The Specialty Care unit drove top-line growth.

Pages: 1...10111213141516

<<<Page 15